Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of BioCentury, Week in Review: Clinical Status

BioCentury, Week in Review Current Issue
  • Flublok: Phase III started

    Protein Sciences Corp., Meriden, Conn. UMN Pharma Inc. (Tokyo:4585), Akita, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Ildong Pharmaceutical Co. Ltd., Seoul, South Korea Product: Flublok (UMN-0502, ASP7374) …

    Published on 2/18/2013
  • GLV-1h68: Phase I started

    Genelux Corp., San Diego, Calif. Product: GLV-1h68 (GL-ONC1) Business: Pulmonary Molecular target: NA Description: Genetically stable modified vaccinia virus that incorporates green fluorescent protein (GFP) to enable …

    Published on 2/18/2013
  • Infradure: Phase I/II started

    Medgenics Inc. (LSE:MEDU; NYSE-M:MDGN), Vienna, Va. Product: Infradure Business: Infectious Molecular target: NA Description: Autologous tissue explants that deliver sustained interferon (IFN) alpha using Medgenics' …

    Published on 2/18/2013
  • LAI287: Phase I started

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: LAI287, NN1436 Business: Endocrine/Metabolic Molecular target: NA Description: Long-acting insulin analog Indication: Treat Type I diabetes Endpoint: …

    Published on 2/18/2013
  • Lysine acetylsalicylate glycine: Phase II started

    Activaero GmbH, Gemuenden, Germany Product: Lysine acetylsalicylate glycine (LASAG) Business: Infectious Molecular target: NA Description: LASAG delivered using Activaero's FAVORITE inhalation delivery technology …

    Published on 2/18/2013
  • MK-3102: Phase III started

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: MK-3102 Business: Endocrine/Metabolic Molecular target: Dipeptidyl peptidase-4 (DPP-4) Description: Once-weekly, oral dipeptidyl peptidase-4 (DPP-4) …

    Published on 2/18/2013
  • OGX-427: Phase II start

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Product: OGX-427 Business: Cancer Molecular target: Heat shock protein 27 (Hsp27) Description: …

    Published on 2/18/2013
  • Omega-3 Cardiac Panel: Clinical trial started

    Nanomix Inc., Emeryville, Calif. Product: Omega-3 Cardiac Panel Business: Diagnostic Molecular target: NA Description: Mobile in vitro diagnostic platform to quantitatively determine cardiac troponin I, myoglobin and …

    Published on 2/18/2013
  • Oral omecamtiv mecarbil: Phase II started

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Product: Oral omecamtiv mecarbil Business: Cardiovascular Molecular target: Cardiac myosin Description: …

    Published on 2/18/2013
  • OTX015: Phase I started

    Oncoethix S.A., Lausanne, Switzerland Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Product: OTX015 Business: Cancer Molecular target: Bromodomain containing 2 (BRD2); Bromodomain containing 3 (…

    Published on 2/18/2013
  • PledOx calmangafodipir: Phase IIb started

    PledPharma AB (SSE:PLED), Stockholm, Sweden Product: PledOx calmangafodipir Business: Hematology Molecular target: Superoxide dismutase 2 mitochondrial (SOD2) (MNSOD) Description: Pyridoxyl ethyldiamine (PLED) analog in…

    Published on 2/18/2013
  • Purified poloxamer 188: QT/QTc study started

    Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif. Product: Purified poloxamer 188 (ANX-188) Business: Hematology Molecular target: NA Description: Antithrombotic poloxamer that adheres to hydrophobic …

    Published on 2/18/2013
  • Recombinant human nerve growth factor: Phase I/II started

    Dompe Farmaceutici S.p.A., Milan, Italy Product: Recombinant human nerve growth factor (rhNGF) Business: Ophthalmic Molecular target: NA Description: Recombinant human nerve growth factor (rhNGF) Indication: Treat stage…

    Published on 2/18/2013
  • SAR407899: Development discontinued

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: SAR407899 Business: Renal Molecular target: Rho kinase Description: Rho kinase inhibitor Indication: Treat diabetic nephropathy Endpoint: NA Status: Development …

    Published on 2/18/2013
  • Sebelipase alfa: Phase III started

    Synageva BioPharma Corp. (NASDAQ:GEVA), Lexington, Mass. Product: Sebelipase alfa (rhLAL) (formerly SBC-102) Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant human lysosomal acid lipase (LAL) …

    Published on 2/18/2013
  • Tamiflu oseltamivir: Clinical trial started

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Tamiflu oseltamivir Business: Infectious Molecular target: Neuraminidase (NEU1) (SIAL1) Description: …

    Published on 2/18/2013
  • Tamiflu oseltamivir: Phase II started

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Tamiflu oseltamivir Business: Infectious Molecular target: Neuraminidase (NEU1) (SIAL1) Description: …

    Published on 2/18/2013
  • Ublituximab: Phase I/II amended

    LFB S.A., Les Ulis, France TG Therapeutics Inc. (OTCBB:TGTX), New York, N.Y. Ildong Pharmaceutical Co. Ltd., Seoul, South Korea Product: Ublituximab (LFB-R603, TGTX-1101) Business: Cancer Molecular target: CD20 …

    Published on 2/18/2013
  • Ularitide: Phase III started

    Cardiorentis AG, Zug, Switzerland Product: Ularitide (ULA01) Business: Cardiovascular Molecular target: NA Description: Intravenous infusion of chemically synthesized form of urodilatin Indication: Treat acute …

    Published on 2/18/2013
  • XmAb5871: Phase Ib/IIa started

    Xencor Inc., Monrovia, Calif. Product: XmAb5871 Business: Autoimmune Molecular target: CD19; Fc gamma receptor IIb (CD32B) (FCGR2B) Description: Humanized mAb targeting CD19 and Fc gamma receptor IIb (CD32B; FCGR2B) …

    Published on 2/18/2013
  • Zybrestat fosbretabulin: Phase II ongoing

    OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif. Product: Zybrestat fosbretabulin (Combretastatin A4P, Zybrestat) Business: Cancer Molecular target: Tubulin Description: A4 prodrug phosphatase-activated tumor …

    Published on 2/18/2013
  • Zymafos palifosfamide: Phase III ongoing

    Ziopharm Oncology Inc. (NASDAQ:ZIOP), New York, N.Y. Product: Zymafos palifosfamide (ZIO-201) Business: Cancer Molecular target: DNA Description: DNA cross-linker shown to bypass resistance mediated by aldehyde …

    Published on 2/18/2013
  • Aleglitazar: Phase III started

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Aleglitazar (R1439, RG1439) Business: Cardiovascular Molecular target: Peroxisome proliferation activated receptor (PPAR) alpha; Peroxisome proliferation …

    Published on 2/11/2013
  • Apocept: Phase I started

    Apogenix GmbH, Heidelberg, Germany Product: Apocept (APG101) Business: Cancer Molecular target: CD95 ligand Description: Soluble fusion protein combining the extracellular domain of CD95 and the Fc portion of IgG …

    Published on 2/11/2013
  • Aranesp darbepoetin alfa: Development discontinued

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Aranesp darbepoetin alfa (NESP) (KRN321) Business: Hematology Molecular target: Erythropoietin (EPO) …

    Published on 2/11/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?